In CLP alone, the Ezh2 inhibitor attenuated kidney damage (serum creatinine) and serum cytokines (TNF-α, IL-6, and IL-10) but not cell-free DNA, endotoxemia, and bacteremia (Figure 9B–J). The gene discussed is IL6; the disease is serum lipopolysaccharide activity.